Search details
1.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Blood
; 141(16): 1971-1981, 2023 04 20.
Article
in English
| MEDLINE | ID: mdl-36626583
2.
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Int J Clin Oncol
; 29(2): 232-240, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38157190
3.
Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.
Cancer Sci
; 113(6): 2085-2096, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35332633
4.
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Hematol Oncol
; 40(4): 667-677, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35142384
5.
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.
Ann Hematol
; 101(5): 979-989, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35244756
6.
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Int J Clin Oncol
; 27(1): 224-233, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34599726
7.
Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.
Cancer Sci
; 112(1): 331-338, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33075165
8.
Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
Cancer Sci
; 112(6): 2426-2435, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33792128
9.
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Cancer Sci
; 112(7): 2845-2854, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33942442
10.
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
BMC Cancer
; 21(1): 358, 2021 Apr 06.
Article
in English
| MEDLINE | ID: mdl-33823836
11.
Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
Jpn J Clin Oncol
; 51(1): 70-77, 2021 Jan 01.
Article
in English
| MEDLINE | ID: mdl-33029633
12.
Occurrence of Infusion-Related Reactions due to Obinutuzumab Therapy for Follicular Lymphoma.
Gan To Kagaku Ryoho
; 48(11): 1369-1373, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34795129
13.
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
Cancer Sci
; 111(9): 3327-3337, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32639651
14.
Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Jpn J Clin Oncol
; 50(11): 1265-1273, 2020 Oct 22.
Article
in English
| MEDLINE | ID: mdl-32776097
15.
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Support Care Cancer
; 28(2): 571-579, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31093770
16.
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Blood
; 130(4): 489-500, 2017 07 27.
Article
in English
| MEDLINE | ID: mdl-28522442
17.
Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance.
Ann Hematol
; 97(2): 289-297, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29138885
18.
Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Cancer Sci
; 108(5): 1007-1012, 2017 May.
Article
in English
| MEDLINE | ID: mdl-28267244
19.
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer
; 25(11): 3313-3320, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28551843
20.
Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma.
Rinsho Ketsueki
; 58(8): 1006-1013, 2017.
Article
in Japanese
| MEDLINE | ID: mdl-28883263